A new review highlights SETDB1 as a key player in osteosarcoma, promoting tumor growth, immune evasion and therapy resistance. Blocking SETDB1 could enhance immunotherapy and chemotherapy ...

I don’t know how anybody could do it without faith in God,’ Amy said. ‘But… God watched his Son suffer and Mary watched her Son suffer —it’s all faith and family that we turn to in the darkest and ...

A new review was published in Oncotarget, Volume 16, on February 12, 2025, titled “SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types.” ...

New York Times reporter Jeremy Peters and Princeton University Professor Eddie Glaude join Chris Jansing to discuss President Trump expanding and defending Elon Musk’s power to make cuts to federal ...

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

A brave nine-year-old girl will have her leg amputated after a fall at after-school care led to a shocking diagnosis.

These funds are earmarked for finalizing the OST-HER2 osteosarcoma trial payments, manufacturing for FDA approval, and other operational costs, including the commercialization of the product.